久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Aramchol? reduces fibrosis progression in 24 weeks EuropeanPharmaceuticalReview
    November 02, 2021
    Galmed Pharmaceuticals has announced results from the first 16 patients in the open-label part of the ARMOR? Phase III study who underwent a scheduled post-baseline biopsy and were treated with Aramchol? for fibrosis.
  • Galmed Initiated Study of Aramchol in Subjects with NASH and Fibrosis americanpharmaceuticalreview
    September 27, 2019
    Galmed Pharmaceuticals announced the initiation of its Phase 3/4 ARMOR clinical study to evaluate the efficacy and safety of Aramchol in subjects with NASH and fibrosis. This double-blind, placebo-controlled ...

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service